Market research
ZGNX Zogenix Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 38
- Dividend yield
- 0.0%
- Beta
- 0.9
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- ISIN
- US98978L2043
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 38
- Dividend yield
- 0.0%
- Beta
- 0.9
About
About Zogenix Inc
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ZGNX discussion.
5 years, 4 months ago
Zogenix, Inc is currently in a long term downtrend where the price is trading 10.6% below its 200 day moving average.
From a valuation standpoint, the stock is 94.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 77.6.
Zogenix, Inc's total revenue rose by 336.2% to $9M since the same quarter in the previous year.
Its net income has dropped by 25.2% to $-70M since the same quarter in the previous year.
Finally, its free cash flow fell by 27.8% to $-44M since the same quarter in the previous year.
Based on the above factors, Zogenix, Inc gets an overall score of 2/5.